Koselugo Meets Primary Endpoint in KOMET Phase III Trial for Adult Neurofibromatosis Type 1
核心洞察
AstraZeneca's Koselugo demonstrated a statistically significant and clinically meaningful objective response rate versus placebo in adults with neurofibromatosis type 1 (搜索) (NF1).
The KOMET trial is the largest global, randomized, double-blind, placebo-controlled Phase III trial in adults with symptomatic, inoperable plexiform neurofibromas (搜索).
The safety profile of Koselugo in the adult trial was consistent with previous trials in children and adolescents, with no new safety signals identified.
AstraZeneca's Koselugo (selumetinib), an oral selective MEK (搜索) inhibitor, met its primary endpoint in the KOMET Phase III trial, demonstrating a statistically significant and clinically meaningful objective response rate (ORR) compared to placebo in adult patients with neurofibromatosis type 1 (搜索) (NF1) and symptomatic, inoperable plexiform neurofibromas (搜索). The KOMET trial is the largest global, randomized, double-blind, placebo-controlled multicenter Phase III trial conducted in this patient population.
KOMET Trial Details and Results
The ORR was defined as the percentage of patients with confirmed complete or partial response by cycle 16, as determined by independent central review per response evaluation in neurofibromatosis and schwannomatosis criteria. The safety profile of Koselugo in the KOMET trial was consistent with that observed in previous clinical trials involving children and adolescents with NF1. No new safety signals were identified in the adult population.
Neurofibromatosis Type 1 (NF1) Context
NF1 is a rare, progressive genetic condition affecting an estimated 1.7 million individuals worldwide, with approximately 70% of those affected being adults. Tumors develop on the nerve sheaths in 30-50% of patients, potentially causing debilitating symptoms such as disfigurement, dysfunction, and persistent pain, often requiring multiple surgeries. NF1 is typically diagnosed in early childhood, but the condition often progresses into adulthood. Currently, there are no approved treatments specifically for adults with NF1, leaving a significant unmet medical need.
Future Steps
Alexion, AstraZeneca Rare Disease will share these data with regulatory authorities and present the findings at an upcoming medical meeting. AstraZeneca and MSD are jointly developing and commercializing Koselugo globally.